For example, Sanmamed et al. demonstrated that early changes in serum interleukin-8 (IL-8) level reflect and predict response to anti-PD-1 therapy in patients with metastatic melanoma and NSCLC. The gene discussed is CXCL8; the disease is non-small cell lung carcinoma.